Key takeaways from the draft 2026 Merger Guidelines and practical advice.
Life science
For compliance professionals attending the annual conference, the takeaway was hard to miss: 2026 will require a more rigorous compliance framework and transparency.
As advancements in research and drug development become more complex, bioethicists are helping companies find their footing along an increasingly ambiguous path.
Many life sciences and healthcare companies develop or deploy AI-based medical devices and digital health solutions that may fall within the high-risk category.
We explored how small and mid-sized pharmaceutical and biotech companies can avoid costly early compliance mistakes and minimize risk as they scale.